ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn

Forefront of Modern Innovative Medicine

Beta Cell Destruction & Restoration

Fluorescence immunostaining of the islets for insulin (beta cell; green) and glucagon (alpha cell; red): Endogenously induced Prostaglandin E2 (Inflammation)-dependent destruction of Beta cells in C57BL/6 mice 

Mission Statement

Improve the lifestyle and lifespan of Type 2 diabetes patients by providing sustained glycemic control

RK-01: A Think-Outside-The-Box Approach To Sustained Glycemic Control 

Type 2 diabetes is characterized by pancreatic beta cell failure and insulin resistance. It continues to be an unmet medical need because currently marketed "me-too" drugs are inadequate in filling one of the most important gaps in the space: sustained glycemic control, with a focus on preserving beta cell function and decreasing insulin resistance. 

~50% of over 1 million newly diagnosed patients experienced primary failure with Metformin (the current first-line of therapy) and secondary failure with second and third add-on antidiabetes drugs from 2005 to 2016 in real-world clinical practice in the United States (Montvida, O. et al. Diabetes Care 2018).

RK-01 is an innovative, patient-centric drug. It is custom-designed and formulated to prevent beta cell failure and decrease insulin resistance. Results from the translational animal studies suggest that it can prevent failure of Metformin treatment.

Results obtained from the animal studies as well as controlled clinical studies support the scientific rationale and the product concept.

Type 2 diabetes patients with high blood pressure (>85%) as well as arthritis as a coexisting condition (>47% of the adults with diabetes) are underserved by the currently marketed drugs.

The U.S. FDA has approved ARKAY's IND application for evaluating RK-01 in adult obese type 2 diabetes patients with high blood pressure and arthritis ( Identifier: NCT03686657).  

Currently raising capital for the human clinical study. 

CEOCFO Magazine

"A 'Beta-cell centric' triple combination of Metformin, an Angiotensin II Receptor Type I Blocker (ARB) and a selective Cyclooxygenase-2 Inhibitor show promise of providing long-term glycemic control for Type 2 diabetes patients"

The proposed doses of selective Cyclooxygenase-2 (Cox-2) inhibitor, Celecoxib* are safe for chronic use in patients with cardiovascular disease risk.

“As the founder and innovator, before I could ask others to invest in my company, I wanted to make sure that I take the risk with my money and establish the proof-of-concept, which we have accomplished already”

Dr. Ravi Kumar
October 3, 2016 Issue

Read Full Article

*April 25, 2018: The FDA's Arthritis Advisory Committee (AAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) voted by a large margin (15:5) that  CV safety of Celecoxib is comparable to Naproxen and Ibuprofen.

Value, Mitigation of Risk & Competitive Edge

In spite of the development of drugs for newer modalities such as GLP-1s, DPP4 inhibitors, and SGLT2 inhibitors, Metformin continues to be the "Gold Standard" for Type 2 diabetes patients. RK-01 adds value by preventing primary and secondary failure of Metformin therapy. ARKAY has mitigated the risk to a great extent because the component add-on drugs have shown efficacy in preserving beta cell function and insulin sensitivity in controlled clinical trials–they also have a track record of safety for chronic use in Type 2 diabetes patients. RK-01 is expected to have a competitive edge based on clinical differentiation and pricing.  

Immune Dysregulation-Inflammation-Insulin Resistance Axis

“I agree that you have an interesting angle and great leadership/SAB advice. There is definitely a lot of unmet medical need in this area and I think that targeting inflammation has a lot of potential. I hope your efforts are highly successful!”

Christopher K. Glass, M.D., Ph.D.
Professor of Cellular & Molecular Medicine
Professor of Medicine

Ben & Wanda Hildyard
Chair in Hereditary Diseases School of Medicine
University of California, San Diego

Striving to End the Epidemic of Type 2 Diabetes

Medicine Tablets

Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 restored efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring RK-01 to market by 2023.


ARKAY is advancing the ParamAushadam® (derived from Sanskrit, it means "Perfect Medicine" in English) platform by combining drugs at the appropriate doses along with predetermined modified drug release to achieve optimal therapeutic as well as kinetic synergies.


Discover why now is the best time to partner and collaborate with our biopharmaceutical company. ARKAY Therapeutics is focused on setting the standard for medicine and treatment of Type 2 diabetes and related disorders such as NASH by advancing an innovative 'Beta-cell-centric' platform.


Invest in a healthier future by becoming a key stakeholder today at ARKAY Therapeutics

Call (609) 362-6818

About Us

With the numbers and cases of diabetes always on the rise with no end in sight, our biopharmaceutical company in East Windsor, New Jersey, decided to take action and do something about this global epidemic. Today, ARKAY Therapeutics is dedicated to developing and commercializing innovative medicines for Type 2 diabetes and preventing the onset of Type 2 diabetes in prediabetic patients.

More than 370 million people worldwide and 26 million people in the U.S. alone suffer from Type 2 diabetes. The disease is not successfully controlled in almost 50% of patients, according to the American Diabetes Association.

The potential impact of our diabetes medicine has enormous medical and financial implications. This is an avenue that investors can’t afford to miss.

Learn More About ARKAY Therapeutics

More Than 30 Years of BioMedical Experience


Thank you for your interest. For questions or comments, please use the information listed here. We look forward to hearing from you soon.

(609) 362-6818

Hours of Operation
Reach Us via Email 24 Hours a Day, 7 Days a Week

Service Area
Open to Investors Worldwide